Introduction

Docetor 20 mg (Docetaxel) Injection represents a significant advancement in cancer treatment therapy, offering hope and improved outcomes for patients battling various forms of cancer. This premium-quality medication, manufactured by the renowned Eskayef Pharmaceuticals Ltd. and supplied by Orio Pharma, is a potent microtubule inhibitor that has demonstrated remarkable efficacy across multiple cancer types. With its precise mechanism of action and comprehensive treatment protocols, Docetor 20 mg has become an essential component in modern oncology treatment regimens worldwide.

Comprehensive Treatment Applications

Docetor 20 mg (Docetaxel) Injection exhibits versatility in treating several cancer types, making it an invaluable asset in oncology practices:

Breast Cancer (BC): Docetor serves as an effective single agent for locally advanced or metastatic breast cancer following chemotherapy failure. Additionally, when combined with doxorubicin and cyclophosphamide, it provides adjuvant treatment for operable node-positive breast cancer, significantly improving patient outcomes.

Non-small Cell Lung Cancer (NSCLC): For patients with locally advanced or metastatic NSCLC who have experienced platinum therapy failure, Docetor functions as a reliable single agent. When administered with cisplatin, it effectively treats unresectable, locally advanced, or metastatic untreated NSCLC.

Castration-Resistant Prostate Cancer (CRPC): When used in conjunction with prednisone, Docetor delivers targeted treatment for patients suffering from metastatic castration-resistant prostate cancer, addressing a challenging condition with limited treatment options.

Gastric Adenocarcinoma (GC): Docetor, when combined with cisplatin and fluorouracil, creates a powerful treatment regimen for untreated, advanced gastric adenocarcinoma, including cancers of the gastroesophageal junction.

Squamous Cell Carcinoma of the Head and Neck (SCCHN): As part of an induction treatment protocol with cisplatin and fluorouracil, Docetor effectively targets locally advanced SCCHN, providing patients with improved therapeutic outcomes.

Advanced Pharmacological Mechanism

The exceptional effectiveness of Docetor 20 mg stems from its sophisticated mechanism of action as an antineoplastic agent. Docetaxel functions by disrupting the microtubular network in cancer cells – a critical component for vital mitotic and interphase cellular functions. The medication promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.

By binding to free tubulin, Docetor decreases the critical intracellular concentration of tubulin needed for cell division. This promoted polymerization leads to the production of microtubule bundles without normal function and stabilizes these structures, effectively inhibiting mitosis in cancer cells. Unlike other spindle poisons, Docetor’s binding to microtubules does not alter the number of protofilaments in the bound microtubules.

Laboratory studies have confirmed Docetor’s cytotoxic properties against various murine and human tumor cell lines, as well as freshly excised human tumor cells in clonogenic assays. Notably, Docetor has demonstrated effectiveness against cell lines that overexpress p-glycoprotein, which is encoded by the multidrug resistant gene – a significant advantage in treating resistant cancers.

Precise Dosage and Administration Guidelines

For optimal therapeutic outcomes, Docetor 20 mg must be administered in a facility equipped to manage potential complications such as anaphylaxis. The injection is delivered intravenously over one hour every three weeks. Important administration notes include avoiding PVC equipment and using only a 21-gauge needle for withdrawal from the vial.

Dosage recommendations vary by cancer type:

• Breast Cancer (locally advanced or metastatic): 60-100 mg/m² as a single agent
• Breast Cancer (adjuvant): 75 mg/m² administered one hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² every three weeks for six cycles
• NSCLC (after platinum therapy failure): 75 mg/m² as a single agent
• NSCLC (chemotherapy-naive): 75 mg/m² followed by cisplatin 75 mg/m²
• Hormone-Refractory Prostate Cancer: 75 mg/m² with 5 mg prednisone twice daily continuously
• Gastric Cancer: 75 mg/m² followed by cisplatin 75 mg/m² (day 1 only) and fluorouracil 750 mg/m² per day as a 24-hour IV (days 1-5)
• SCCHN: Specific protocols involving cisplatin and fluorouracil for either 3 or 4 cycles

All patients should receive oral corticosteroid premedication, with dosage adjustments as clinically indicated.

Safety Profile and Considerations

Healthcare providers should be aware of Docetor’s comprehensive safety profile to ensure optimal patient outcomes:

Contraindications: Docetor should not be administered to patients with neutrophil counts below 1,500 cells/mm³ or those with a history of severe hypersensitivity reactions to docetaxel or polysorbate 80.

Drug Interactions: As a CYP3A4 substrate, Docetor’s metabolism may be modified by compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, necessitating careful medication review.

Common Side Effects: Patients may experience infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia. Incidence varies by indication.

Special Precautions: Docetor administration requires supervision by physicians experienced with antineoplastic agents. Higher risks exist for patients with hepatic impairment, including toxic death and fatal gastrointestinal hemorrhage. Healthcare providers should monitor for enterocolitis, severe hypersensitivity reactions, and treatment-related acute myeloid leukemia.

Pregnancy, Lactation, and Storage

Based on animal studies and its mechanism of action, Docetor can cause fetal harm when administered during pregnancy. Information regarding its presence in human milk or effects on breastfeeding is unavailable, necessitating careful consideration for nursing mothers.

To maintain product integrity, store Docetor 20 mg between 2°C and 25°C, protected from light. While freezing does not adversely affect the product, proper storage ensures maximum efficacy.

Quality Assurance

Docetor 20 mg is manufactured by Eskayef Pharmaceuticals Ltd., a leading pharmaceutical company in Bangladesh with over 31 years of experience in producing world-class medicines. Since its acquisition by the reputed Transcom Group in 1990, Eskayef has established itself as the epitome of premium quality in pharmaceutical manufacturing.

Orio Pharma, established in June 2019, serves as a trusted supplier of anti-cancer and oncology medicines worldwide. Committed to the highest standards of quality and excellence, Orio Pharma ensures that each product, including Docetor 20 mg, meets stringent quality standards and regulatory requirements.

Conclusion

Docetor 20 mg (Docetaxel) Injection represents a cornerstone therapy in modern cancer treatment, offering healthcare providers a powerful tool in combating various malignancies. With its proven efficacy, detailed administration protocols, and comprehensive safety profile, Docetor continues to play a vital role in improving outcomes for cancer patients globally. Available through Orio Pharma with worldwide delivery within 3-7 working days, this premium-quality medication exemplifies the commitment to excellence in cancer care by both manufacturer and supplier.